Bioartificial Organ Market Size to Reach USD 105.2 Million in 2032
The bioartificial organ market size was USD 26.3 Million in 2024 and is expected to register a revenue CAGR of 19.6% during the forecast period
February 1st, 2025 – Shortages of donor organs for transplantation contributing to revenue growth of the bioartificial organ market. This scarcity is rising owing to restricted donor availability, organ rejection concerns, and post-transplant problems. According to the Health Resources and Services Administration (HRSA) of the United States Department of Health, there are presently 103,223 patients on the transplant waiting list, including men, women, and children, with 17 individuals dying per day while waiting for an organ transplant.
increasing elderly population represents a substantial growth opportunity for the bioartificial organ market. According to the World Health Organization (WHO), by 2030, one in every six individuals will be 60 years or older, and by 2050, 80% of older persons will live in low-or-middle-income nations. Older people are more likely to have organ failure, creating a significant opportunity to fulfill the rising need for bioartificial organs that can alleviate organ donation shortages.
3D bioprinting brings up new possibilities for customized implants and tissue regeneration. Tissue engineering and bioartificial tissue creation are developing therapeutic strategies for replacing damaged organs. Tissue engineering has the potential to solve significant organ shortages while also enhancing the treatment of illnesses such as chronic lung problems, heart failure, and liver disease. In addition, human bio-artificial muscle (BAM), scaffold geometry, and biomaterial selection in 3D bioprinting are driving industry advances.
However, owehigh production costs are a key impediment to the revenue growth of the bioartificial organ market. The high expense associated with producing bioartificial organs due to research and development (R&D) is restricting their wider acceptance, particularly among patients with financial constraints. These costs are increasing the overall costs involved with the transplantation surgery.
Key Highlights:
- Bioartificial kidney contributed the largest revenue share in 2024. The increasing incidence of renal illness is a major factor driving revenue share growth in this market. Chronic kidney disease, along with acute renal failure (ARF), is becoming a major issue, with ARF death rates among ICU patients reaching.
- Tissue regeneration & repair segment is expected to register fastest revenue growth over the forecast period. Advances in regenerative medicine, tissue engineering, and 3D bioprinting are likely to drive market revenue growth over the projection period. Regenerative medicine is the branch of medicine and biology that studies the regeneration of tissues or organs. Tissue engineering and 3D bioprinting can assist in regenerating tissues with complicated shapes. These advances are creating new prospects for the treatment of chronic ailments like heart disease, renal failure, and liver damage.
- Asia Pacific is expected to register fastest revenue growth by 2032. The increasing prevalence of chronic kidney disease (CKD) is driving revenue growth in this region. Bioartificial organs are increasingly being used to treat chronic kidney disease (CKD), owing to a growing shortage of kidney transplants. The Korean Society of Nephrology estimates that chronic kidney disease (CKD) affects 434 million people in Eastern, Southern, and Southeastern Asia, with around 65 million in stages 4-5.
- Some major companies in the global bioartificial organ market report include United Therapeutics Corporation, Miromatrix Medical Inc., IVIVA Medical, Inc., Organovo Holdings, Inc., Humacyte Global, Inc., Athersys, Inc., Organogenesis Inc., XenoTherapeutics Foundation, BioLife Solutions Inc., Pandorum International Inc.
- On 13th June 2023, IVIVA Medical, a biotechnology business focussing on producing live medicines to treat organ failure, was recognized for its pioneering achievement in creating a completely implanted bioartificial kidney with 3D printing technology. As part of the competition, IVIVA will get USD 1 million to expand its research and develop cell-based living medicines that mimic the kidney’s critical activities.
Unlock the key to transforming your business strategy with our bioartificial organ market insights –
Navistrat Analytics has segmented Bioartificial organ market in the areas of organ type, cell type, material type, application, end-use and region:
- Organ Type Outlook (Revenue, USD Million; 2022-2032)
- Bioartifical Kidney
- Bioartifical Liver
- Bioartifical Heart
- Bioartifical Lung
- Bioartifical Pancreas
- Others
- Cell Type Outlook (Revenue, USD Million; 2022-2032)
- Autologous Cells
- Allogenic Cells
- Xenogeneic Cells
- Stem Cells
- Material Type Outlook (Revenue, USD Million; 2022-2032)
- Synthetic Polymers
- Polylactic Acid (PLA)
- Polyglycolic Acid (PGA)
- Polycaprolactone (PCL)
- Polyethylene Glycol (PEG)
- Others
- Natural Polymers
- Collagen
- Fibrin
- Chitosan
- Alginate
- Carbohydrates
- Hyaluronic Acid
- Dextran
- Agarose
- Decellularized Natural Tissues
- Others
- Synthetic Polymers
- Application Outlook (Revenue, USD Million; 2022-2032)
- Organ Transplantation
- Tissue Regeneration & Repair
- Drug Discovery and Testing
- Others
- End-Use Outlook (Revenue, USD Million; 2022-2032)
- Hospitals & Transplant Centers
- Biotechnology & Biopharmaceutical Companies
- Research Institutes & Academic Laboratories
- Regional Outlook (Revenue, USD Million; 2022-2032)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Benelux
- Nordic Countries
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Oceania
- ASEAN Countries
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- GCC Countries
- South Africa
- Israel
- Turkey
- Rest of MEA
- North America